Your AI-Trained Oncology Knowledge Connection!
Multiple myeloma experts share background for discussion of the recent publication, “Survival benefit of ixazomib, lenalidomide and dexamethasone [IRD] over lenalidomide and dexamethasone [Rd] in relapsed and refractory multiple myeloma patients in routine clinical practice.”
Drs Fanning and Richter review the baseline characteristics of patients included in the routine clinical practice publication of ixazomib, lenalidomide, and dexamethasone [IRD] versus lenalidomide and dexamethasone [Rd] in patients with relapsed/refractory multiple myeloma.
Suzanne Fanning, DO, and Joshua Richter, MD discuss efficacy outcomes seen in a routine clinical practice study of ixazomib, lenalidomide and dexamethasone [IRD] compared with lenalidomide and dexamethasone [Rd] in patients with relapsed/refractory multiple myeloma.
Experts provide commentary on the subgroup analyses from real-world data on use of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Data review of IRD vs Rd in patients with relapsed/refractory multiple myeloma who had a prior autologous stem cell transplant or extramedullary disease.
Two experts discuss cytogenetic profiles in patients with relapsed/refractory multiple myeloma treated with either doublet or triplet therapy.
Hematologic oncologists discuss toxicities seen with ixazomib, lenalidomide, and dexamethasone (IRd) compared with lenalidomide and dexamethasone (Rd).
Experts summarize key points from routine clinical practice on use of ixazomib, lenalidomide, and dexamethasone (IRD) in patients with relapsed/refractory multiple myeloma.
Drs Richter and Fanning discuss next steps and future directions in the management of patients with relapsed/refractory multiple myeloma.
Suzanne Fanning, DO, and Joshua Richter, MD, discuss clinical implications of a real-world study of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
